A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) for People With Recurrent Glioblastoma With Elevated Mutational Burden

Conditions:   Glioblastoma, IDH-Mutant;   Recurrent Glioblastoma Interventions:   Biological: Ipilimumab;   Biological: Nivolumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials